A retrospective review sought to better understand the relationship between bortezomib and lenalidomide therapy and treatment-induced skin rash in multiple myeloma.
Researchers sought to determine the potential risk of cardiovascular mortality vs risk of disease recurrence in patients with early-stage HL receiving IFRT after ABVD.
As myeloproliferative neoplasms (MPN) are a particularly rare form of blood cancer without a clear cause, it may be difficult to understand how lifestyle factors can affect both MPN risk and symptom burden. What has research suggested about the ways certain lifestyle factors affect MPNs?
